Blue River Bio

Pain relief should never come at the cost of addiction

Despite decades of research, opioids remain the only effective option for moderate to severe acute pain, leaving patients and their clinicians trapped between uncontrolled pain and the unacceptable risk of addiction

1: Gan et al. Journal of Pain Research, 2017. 2: Ladha et al. JAMA Network Open, 2019. 3: Stark et al. Anaesthesia and Intensive Care, 2017. 4: Spencer et al. National Center for Health Statistics, 2022. 5: Florence et al. Drug and Alcohol Dependence, 2017.

Developing the world’s first pain medication as powerful as opioids but without the risk of addiction

Pain relief should never come at the cost of addiction

>80%

do not receive adequate pain management after surgery¹

75%

fill a postop opioid prescription, 25% become long-term users^2,3

>100,000

annual deaths in the U.S. alone⁴

Billions

of dollars in healthcare costs⁵

The Blue River Bio Solution

We are developing an oral therapy to deliver opioid-level pain relief without addiction risk, grounded in our team’s deep and diverse scientific, clinical, and translational expertise:

Systems Neuroscience

Biostatistics & Causal Inference

Analgesic Pharmacology

Clinical Trial Design

Early Traction Through Leading Translational and Founder Programs

Vetted by leaders in medicine, biotechnology, patent licensing, commercial pharma & biotech, and venture capital

Stanford SPARK Translational Program

Stanford OTL High Impact Technology (HIT) Fund

Stanford-Coulter Translational Research Grant

Stanford StartX Start-Up Accelerator

Want to Learn More?

Reach out and we will update you on our progress

Developing the world’s first pain medication as powerful as opioids but without the risk of addiction

Pain relief should never come at the cost of addiction

>80%

do not receive adequate pain management after surgery1

75%

fill a postop opioid prescription, 25% become long-term users2,3

>100,000

annual deaths in the U.S. alone4

Billions

of dollars in healthcare costs5

The Blue River Bio Solution

We are developing an oral therapy to deliver opioid-level pain relief without addiction risk, grounded in our team’s deep and diverse scientific, clinical, and translational expertise:

Systems Neuroscience

Biostatistics & Causal Inference

Analgesic Pharmacology

Clinical Trial Design

Early Traction Through Leading Translational and Founder Programs

Vetted by leaders in medicine, biotechnology, patent licensing, commercial pharma & biotech, and venture capital

Stanford SPARK Translational Program

Stanford OTL High Impact Technology (HIT) Fund

Stanford-Coulter Translational Research Grant

Stanford StartX Start-Up Accelerator

Want to Learn More?

Reach out and we will update you on our progress

do not receive adequate pain management after surgery¹

fill a postop opioid prescription, 25% become long-term users^2,3

annual deaths in the U.S. alone⁴

of dollars in healthcare costs⁵